New PET tracer shows promise for spotting myeloma bone lesions

NCT ID NCT03891914

Completed Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks. The goal is to find a more accurate, one-stop imaging method for initial staging and treatment monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-choline and 18F-FDG (radiopharmaceutical tracers used in PET/CT imaging)
What this could lead to: If successful, this could lead to a more accurate imaging method for diagnosing multiple myeloma, potentially replacing the need for multiple scans.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply to all patients. The new tracer may not prove significantly better than the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

Bordeaux University Hospital - Haut-Lévêque

Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.